These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1698858)

  • 1. Characterization of eosinophil cell activation by peptides. Differential effects of substance P, melittin, and FMET-Leu-Phe.
    Kroegel C; Giembycz MA; Barnes PJ
    J Immunol; 1990 Oct; 145(8):2581-7. PubMed ID: 1698858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
    Giembycz MA; Kroegel C; Barnes PJ
    J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4.
    Munoz NM; Vita AJ; Neeley SP; McAllister K; Spaethe SM; White SR; Leff AR
    J Pharmacol Exp Ther; 1994 Jan; 268(1):139-43. PubMed ID: 8301549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FMLP is a potent activator of guinea-pig eosinophils but its activity is dependent on the prior overnight in vitro culture of the cells (facilitation).
    Bach MK; Brashler JR
    Immunology; 1992 Apr; 75(4):680-7. PubMed ID: 1317350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release.
    Moy JN; Gleich GJ; Thomas LL
    J Immunol; 1990 Oct; 145(8):2626-32. PubMed ID: 2170521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taurine chloramine inhibits functional responses of human eosinophils in vitro.
    Martinez-Losa M; Cortijo J; Piqueras L; Sanz MJ; Morcillo EJ
    Clin Exp Allergy; 2009 Apr; 39(4):537-46. PubMed ID: 19222497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of salbutamol and salmeterol on human eosinophil responses.
    Ezeamuzie CI; al-Hage M
    J Pharmacol Exp Ther; 1998 Jan; 284(1):25-31. PubMed ID: 9435156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of human eosinophil degranulation and activation by endogenous phospholipase A2.
    White SR; Strek ME; Kulp GV; Spaethe SM; Burch RA; Neeley SP; Leff AR
    J Clin Invest; 1993 May; 91(5):2118-25. PubMed ID: 8387540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of human neutrophils by substance P: effect on FMLP-stimulated oxidative and arachidonic acid metabolism and on antibody-dependent cell-mediated cytotoxicity.
    Wozniak A; McLennan G; Betts WH; Murphy GA; Scicchitano R
    Immunology; 1989 Nov; 68(3):359-64. PubMed ID: 2480329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophil activation on biologic surfaces. Production of O2- in response to physiologic soluble stimuli is differentially modulated by extracellular matrix components and endothelial cells.
    Dri P; Cramer R; Spessotto P; Romano M; Patriarca P
    J Immunol; 1991 Jul; 147(2):613-20. PubMed ID: 1712813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Ca2+ in phosphatidylinositol response and arachidonic acid release in formylated tripeptide- or Ca2+ ionophore A23187-stimulated guinea pig neutrophils.
    Takenawa T; Homma Y; Nagai Y
    J Immunol; 1983 Jun; 130(6):2849-55. PubMed ID: 6406597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of LTB4 by fMLP-stimulated alveolar macrophages accounts for eosinophil migration in vitro.
    Hidi R; Coëffier E; Vargaftig BB
    J Leukoc Biol; 1992 May; 51(5):425-31. PubMed ID: 1318347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation.
    Nagata M; Sedgwick JB; Bates ME; Kita H; Busse WW
    J Immunol; 1995 Aug; 155(4):2194-202. PubMed ID: 7543540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils.
    Kita H; Abu-Ghazaleh RI; Sur S; Gleich GJ
    J Immunol; 1995 May; 154(9):4749-58. PubMed ID: 7722326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P activates and modulates neutrophil oxidative metabolism and aggregation.
    Hafström I; Gyllenhammar H; Palmblad J; Ringertz B
    J Rheumatol; 1989 Aug; 16(8):1033-7. PubMed ID: 2479743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism underlying the contractile effect of a chemotactic peptide, formyl-Met-Leu-Phe on the guinea-pig Taenia coli.
    Kawata H; Hirano K; Nishimura J; Kubo C; Kanaide H
    Br J Pharmacol; 2005 Jun; 145(3):353-63. PubMed ID: 15735654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation.
    Ezeamuzie CI; Al-Hage M
    Int Arch Allergy Immunol; 1998 Feb; 115(2):162-8. PubMed ID: 9482706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anti-allergy drugs on fMet-Leu-Phe-stimulated superoxide generation in human neutrophils.
    Hojo M; Hamasaki Y; Fujita I; Koga H; Matsumoto S; Miyazaki S
    Ann Allergy; 1994 Jul; 73(1):21-6. PubMed ID: 7913297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of fMet-Leu-Phe receptor-mediated Ca2+ influx across the plasma membrane of human neutrophils.
    Andersson T; Dahlgren C; Pozzan T; Stendahl O; Lew PD
    Mol Pharmacol; 1986 Nov; 30(5):437-43. PubMed ID: 2430168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.